BioPharma

13 October, 2026 | Tuesday | News

Asieris Pharmaceuticals and Theramex Sign Over $250 Million Licensing Deal for Cervical Precancer Therapy CEVIRA

Agreement is expected to grant Theramex exclusive rights to CEVIRA® in Europe, Australia, New Zealand and Turkey, while Asieris retains rights for the rest of the world. The deal includes 15 million US d...

Lab

14 October, 2026 | Wednesday | News

CellCarta Partners with Waters Corporation to Advance Companion Diagnostics and Next-Generation Flow Cytometry

CellCarta, a leading global CRO laboratory to the biopharmaceutical industry,  announced a strategic partnership with Waters Corporation, a global leader in life sciences and diagnostics, creating a framew...

BioTech

14 October, 2026 | Wednesday | News

China’s Hiteck Biological Pharma Licenses Next-Generation Eye Therapy to Visara for Global Development

Wuhan Hiteck Biological Pharma Co., Ltd.  announced that it has entered into an exclusive license agreement (the "License Agreement") with Visara, Inc. ("Visara"), a majority-owned ophthalmology subsidiary...

Contract Services

14 October, 2026 | Wednesday | News

360biolabs Expands Australian Footprint with New Bioanalytical Laboratory in Sydney

  The new 360biolabs facility in North Ryde is strategically located within one of Sydney’s vibrant science and medtech hubs, Macquarie Park Innovation District alongside a growing community of inno...

Consumer Health

14 October, 2026 | Wednesday | News

Roche Secures Global Rights to Rona Therapeutics’ RNAi Obesity Candidate in Deal Worth Up to $1.16 Billion

- Rona Therapeutics announced it has granted Roche an exclusive worldwide license for Rona's investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's proprietary ex...

Medtech

12 October, 2026 | Monday | News

RingConn Smart Ring Secures US FDA 510(k) Clearance for Non-Invasive Blood Oxygen Monitoring

Shenzhen Ninenovo Technology Limited, the parent company of RingConn, announced that its Smart Ring has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for non-invasive blood oxygen (...

Cell & Gene

13 October, 2026 | Tuesday | News

Nuevocor Doses First Patient in Phase 1/2 Gene Therapy Trial for Inherited Cardiomyopathy

 Nuevocor, a clinical-stage biotechnology company pioneering mechanobiology-targeted therapies designed to address the root causes of life-threatening cardiomyopathies, announced that the first patient has...


Biopharma APAC Infomercial

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close